Maas R A, Dullens H F, Den Otter W
Academisch Ziekenhuis Utrecht, Instituut voor Pathologie, Utrecht, The Netherlands.
In Vivo. 1991 Nov-Dec;5(6):637-41.
We have demonstrated that local treatment with low doses of IL-2 can cure mice bearing a large burden of metastasized SL2 lymphoma. Different mechanisms lead to rejection of ascitic SL2 tumor and solid s.c. SL2 tumor. For local rejection of ascitic tumor cytotoxic T-lymphocytes were essential, whereas the cytotoxic activity of macrophages was also important for tumor rejection. In distant solid tumors very few infiltrating lymphocytes and macrophages were present. Nevertheless, IL-2 treatment rapidly induced necrosis that seemed to be caused by stasis of blood flow in the tumors. This may be mediated by the local release of cytokines like TNF. We conclude that both cytotoxic activity and the production of cytokines by T-cells is essential for IL-2 induced systemic tumor rejection.
我们已经证明，用低剂量白细胞介素-2进行局部治疗可以治愈携带大量转移性SL2淋巴瘤的小鼠。不同的机制导致腹水型SL2肿瘤和皮下实体型SL2肿瘤被排斥。对于腹水型肿瘤的局部排斥，细胞毒性T淋巴细胞至关重要，而巨噬细胞的细胞毒性活性对于肿瘤排斥也很重要。在远处的实体瘤中，很少有浸润淋巴细胞和巨噬细胞。然而，白细胞介素-2治疗迅速诱导坏死，这似乎是由肿瘤内血流停滞引起的。这可能是由肿瘤坏死因子等细胞因子的局部释放介导的。我们得出结论，细胞毒性活性和T细胞产生细胞因子对于白细胞介素-2诱导的全身肿瘤排斥都是必不可少的。
